TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04783363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snoezelen session
Description: before one of two repeated invasive care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snoezelen session
Description: before one of two repeated invasive care
Study: NCT05807698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter therapy
Description: Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
Study: NCT06451536

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga-68 FAPI PET/CT
Description: imaging of FAP expression of tumor before immunotherapy
Study: NCT05071482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib
Description: Flumatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Flumatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Imatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
Study: NCT05354856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: A bolus of ICG (0.2 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline. Gastric perfusion will subsequently be assessed along specific regions of interest (ROI) with q-ICG (quantitative perfusion assessments with ICG) to obtain baseline perfusion values.
Study: NCT05690607

Intervention type: OTHER
Intervention: Doctors Laboratory TINIES small volume blood testing kit
Description: Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.

Intervention type: OTHER
Intervention: Doctors Laboratory TINIES small volume blood testing kit
Description: Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.

Intervention type: OTHER
Intervention: Doctors Laboratory TINIES small volume blood testing kit
Description: Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.

Intervention type: OTHER
Intervention: Doctors Laboratory TINIES small volume blood testing kit
Description: Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.
Study: NCT05892757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ubrogepant
Description: Oral Tablet
Study: NCT05477758

Intervention type: BEHAVIORAL
Intervention: Collaborative care
Description: Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring

Intervention type: BEHAVIORAL
Intervention: Collaborative care
Description: Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
Study: NCT06197438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Leucovorin
Description: Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered on day 1 of each cycle at 90 mg/m2 once every 14 days.
Study: NCT05542147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg
Description: 1 tablet per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day
Study: NCT05229159

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance analysis
Description: Segmental multi-frequency bioelectrical impedance analysis are carried out at all patient admitted to our ICU for postoperative care after cardiac surgery with cardiopulmonary bypass. Our objective is to evaluate the relevance of phase angle to predict mortality or a prolonged hospital length of stay. Phase angle is evaluated at ICU admission and will be compared to well-known prognostic scores computed in preoperative (EuroSCORE II) and at day one after surgery (SOFA, CASUS and SAPS II).
Study: NCT05824702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer education & communications
Description: The intervention trains peer educators to promote medication-assisted drug treatment among peer who inject drugs and are living with HIV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care educational
Description: This is an educational equal attention control group
Study: NCT06416891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.25%
Description: SCPB using 10 ml of bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 2 mg in bupivacaine 0.25%
Description: SCPB using dexamethasone 2 mg in 10 ml of bupivacaine 0.25%
Study: NCT05477758

Intervention type: OTHER
Intervention: Usual General Practitioner (GP) care
Description: Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
Study: NCT05964647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSD (150 µg) + ketanserin (40 mg)
Description: Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSD (150 µg) + olanzapine (10 mg)
Description: Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose
Study: NCT05477758

Intervention type: OTHER
Intervention: Usual General Practitioner (GP) care
Description: Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.

Intervention type: OTHER
Intervention: Usual General Practitioner (GP) care
Description: Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
Study: NCT05964647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSD (150 µg) + lorazepam (2 mg)
Description: Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose
Study: NCT05477758

Intervention type: BEHAVIORAL
Intervention: Behavioral Activation Self-Help guide
Description: Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
Study: NCT06532318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Freshly prepared autologus platelet rich plasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer Depo-medrol
Description: Methylprednisolone acetate 20mg/ml injection
Study: NCT05964647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSD (150 µg) + placebo
Description: Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + placebo
Description: Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study: NCT06035783

Intervention type: DEVICE
Intervention: Orbital Atherectomy
Description: The Diamondback 360° Coronary orbital atherectomy system (OAS) is a device dedicated to debulk severely calcified coronary lesions to facilitate stent delivery and enable stent expansion with optimal results. The OAS's main mechanism is the synergistic rotation of the crown around its axis and simultaneously its endoluminal orbital motion. This effect allows blood to flow continuously and it facilitates heat dispersion which results in reduced heat damage to the arterial walls and subsequently to less myocardial damage, at the same time it softens the plaques tissue. It also appears that the microparticles created from sanding the artery plaques do not create any agglomeration to the branching arteries
Study: NCT06325085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compensatory and restorative rehabilitation techniques
Description: compensatory and restorative rehabilitation techniques Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cognitive rehabilitation training
Description: Naming words ( ask patient to name food, states, family members) Counting numbers backwards, backward counting of days and months) Spell the word backwards, remembering a piece of information Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week.
Study: NCT05673421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming Training
Description: VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Feedback Training
Description: During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
Study: NCT05006937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dusting
Description: Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Basket extraction
Description: Basket extraction is when a small wire basket is used to remove stone fragments.
Study: NCT05738356

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adhesive bonding systems
Description: Three different adhesive bonding systems were used; one system per group

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adhesive bonding systems
Description: Three different adhesive bonding systems were used; one system per group

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive bonding systems
Description: Three different adhesive bonding systems were used; one system per group
Study: NCT05325892

Intervention type: COMBINATION_PRODUCT
Intervention: This is an observational study
Description: This is an observational study

Intervention type: COMBINATION_PRODUCT
Intervention: This is an observational study
Description: This is an observational study
Study: NCT06057285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An ACLs cart training course was developed using augmented reality (AR) technologies
Description: The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
Study: NCT06286553

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trunk exercise
Description: Trunk stabilization exercises including the following components: (a) progressive deep abdominal muscle retraining (transversus abdominis), (b) progressive pelvic floor muscle retraining, (c) abdominal muscle strengthening exercises (rectus abdominis and obliques), (d) combination of abdominal muscle control and distal extremity movements, and (e) progressive functional exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trunk exercise
Description: Trunk stabilization exercises including the following components: (a) progressive deep abdominal muscle retraining (transversus abdominis), (b) progressive pelvic floor muscle retraining, (c) abdominal muscle strengthening exercises (rectus abdominis and obliques), (d) combination of abdominal muscle control and distal extremity movements, and (e) progressive functional exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: Inspiratory muscle strengthening exercises using inspiratory resistance (IMT devices)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants in the Control Group will receive general management information for DRA, written instructions and a single educational exercise session for contracting the deeper abdominals and pelvic floor muscles.
Study: NCT06545292

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring with a dried blood spot and microatainer.
Description: Patients who use an oral oncolytic will be asked to provide twelve microsamples obtained by finger prick (eight dried blood spots (DBS) and four wet blood samples in microtainer EDTA) and four paired whole blood (WB) samples obtained by venapuncture.
Study: NCT06371599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playing game
Description: Active Distraction Methods

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watching cartoon
Description: Passive Distraction Methods
Study: NCT06546683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-Chain Fatty Acids
Description: Colon-delivery capsules of Short-Chain Fatty Acids will be administered in a ratio of 60:20:20, thus 150 mmol of acetate, 50 mmol of propionate and 50 mmol of butyrate equivalent to 20g of fibers, once daily, one week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose will be used as placebo, one daily, one week
Study: NCT04836156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
Description: The choice of chemotherapy is based on the PTC drug sensitivity results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
Description: The choice of chemotherapy is based on the PTC drug sensitivity results.
Study: NCT05174299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic stimulation
Description: For Experimental Arm, active magnetic stimulation on motor cortex followed by active magnetic stimulation on spinal cord, patients underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rTMS) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord. For Active Comparator Arm, active magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord. For Sham Comparator Arm, sham magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: magnetic stimulation
Description: For Experimental Arm, active magnetic stimulation on motor cortex followed by active magnetic stimulation on spinal cord, patients underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rTMS) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord. For Active Comparator Arm, active magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord. For Sham Comparator Arm, sham magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic stimulation
Description: For Experimental Arm, active magnetic stimulation on motor cortex followed by active magnetic stimulation on spinal cord, patients underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rTMS) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord. For Active Comparator Arm, active magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord. For Sham Comparator Arm, sham magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord.
Study: NCT06386757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Video Laryngoscopy (VL) and Bougie
Description: To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation.
Study: NCT04735237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous fat injection
Description: Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical revision with orbicularis oris muscle reconstruction.
Description: Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
Study: NCT06386757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Direct Laryngoscopy (DL) and Bougie
Description: To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation